Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus pemetrexed plus platinum as first-line therapy for unresectable pleural mesothelioma
NL-OMON47222Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pleural mesothelioma comparing Nivolumab + ipilimumab with Pemetrexed + cisplatin or carboplatin (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON47222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47222.